DANBURY, Conn.--(BUSINESS WIRE)--IMS Health Holdings, Inc. (NYSE:IMS), a leading global provider of information and technology services to the healthcare and life sciences industries, today announced results for the quarter ended June 30, 2016.

Second-Quarter 2016 Operating Results

Revenue for the second quarter of $802 million increased 8.1 percent on a reported basis and 8.4 percent on a constant currency basis, compared with the second quarter of 2015.

Technology services revenue grew 13.8 percent in the second quarter on a reported basis and 14.3 percent on a constant currency basis versus the same period last year. Information offerings revenue was up 2.5 percent reported and 2.6 percent on a constant currency basis. Emerging markets revenue increased 5.4 percent in the second quarter on a reported basis and 11.0 percent at constant currency. Developed markets revenue grew 8.7 percent on a reported basis and 7.9 percent at constant currency.

Adjusted EBITDA of $238 million improved 8.1 percent on a reported basis and 6.7 percent on a constant currency basis, compared with the second quarter of 2015.

“We delivered another quarter of consistent revenue and earnings performance,” said Ari Bousbib, chairman and CEO, IMS Health. “We are looking forward to the pending merger with Quintiles and the benefits that will accrue to our customers, shareowners and employees.”

Second-quarter 2016 net income was $24 million compared to $47 million in last year’s second quarter, with the decline principally attributable to higher restructuring charges in 2016. Adjusted Net Income for the second quarter was $139 million, up 10.7 percent on a reported basis and 15.7 percent on a constant currency basis.

Diluted earnings per share was $0.07 in the second quarter, compared with $0.14 per share in the second quarter of 2015. Adjusted Diluted Earnings per Share of $0.41 increased 12.2 percent reported and 17.3 percent on a constant currency basis, reflecting the higher Adjusted Net Income and lower shares outstanding.

First-Half 2016 Operating Results

Revenue of $1,576 million for the first six months of 2016 increased 14.7 percent reported and 16.1 percent on a constant currency basis, compared with the first half of 2015. Excluding the first quarter impact of the Cegedim acquisition, which closed on April 1, 2015, revenue for the six months ended June 30, 2016 was up 8.6 percent on a constant currency basis.

Adjusted EBITDA of $474 million increased 8.7 percent on a reported basis and 8.0 percent on a constant currency basis, compared with the first half of 2015. First-half net income was $67 million, compared with net income of $345 million last year. Beginning in the first quarter of 2015, IMS Health has asserted that its non-U.S. earnings would be indefinitely reinvested outside the U.S., with the company no longer accruing taxes on those foreign earnings at the higher U.S. tax rate. This resulted in a $256 million non-cash income tax benefit in last year’s first quarter from a one-time reduction in the deferred tax liability. Adjusted Net Income, which excludes this one-time, non-cash tax benefit, increased to $279 million in this year’s first half, up 6.8 percent on a reported basis and 10.9 percent at constant currency.

Diluted earnings per share was $0.20 in the first half of 2016, compared with $1.01 per share in the prior-year period. Adjusted Diluted Earnings per Share of $0.83 in the first half increased 9.1 percent on a reported basis and 13.2 percent on a constant currency basis.

Financial Position

As of June 30, 2016, cash and cash equivalents were $368 million and the principal amount of debt was $4,565 million, resulting in net debt of $4,197 million. At the end of the second quarter, IMS Health’s Gross Leverage Ratio was 4.9 times trailing 12-month Adjusted EBITDA, compared with 4.8 times at December 31, 2015.

During the second quarter, IMS Health spent $25 million to repurchase 1.0 million shares of its common stock.

Cash Flow

Cash flow from operating activities was $111 million in the second quarter, compared with a strong $186 million in the second quarter of 2015, with the difference principally reflecting growth in accounts receivable and timing of cash flows related to loyalty card programs the company administers on behalf of its customers. Cash flows in these programs can fluctuate significantly from quarter to quarter. Capital expenditures and additions to deferred software of $53 million increased by $7 million versus the second quarter of 2015. Unlevered Free Cash Flow for the second quarter was $153 million, or 64 percent of Adjusted EBITDA.

2016 Full-Year and Third-Quarter Guidance

For the 2016 full year on a reported basis, IMS Health is increasing its revenue growth guidance by 1 percentage point to 10 to 12 percent, Adjusted EBITDA growth by 1 percentage point to 8.5 to 10.5 percent, Adjusted Net Income growth by 3 percentage points to 5 to 7 percent, and Adjusted Diluted Earnings per Share growth by 3 percentage points to 7 to 9 percent.

On a constant currency basis, IMS Health reaffirms full-year 2016 guidance for revenue to grow 10 to 12 percent and Adjusted EBITDA to grow 7.5 to 9.5 percent, and raises guidance on Adjusted Net Income and Adjusted Diluted Earnings per Share growth by 1.5 percentage points to 8 to 10 percent and 10 to 12 percent, respectively.

For the third quarter on a reported basis, IMS Health expects revenue and Adjusted EBITDA to grow by 8 to 9 percent, while Adjusted Net Income will decline 1 to 2 percent and Adjusted EPS will decline 0.5 to 1.5 percent.

On a constant currency basis, the company expects third-quarter revenue to grow by 7.5 to 8.5 percent, Adjusted EBITDA to grow by 4 to 5 percent, Adjusted Net Income to grow by 0 to 1 percent and Adjusted Diluted EPS to grow by 1.5 to 2.5 percent.

All reported guidance assumes that current foreign currency exchange rates hold constant through the end of 2016.

IMS Health reports results in U.S. dollars, but does business on a global basis. Exchange rate fluctuations affect the U.S. dollar value of foreign currency revenue and expenses and may have a significant effect on reported results. The discussion of IMS Health’s financial results in this release includes comparisons with the prior year in constant currency terms, using consistent exchange rates. Management believes this information facilitates comparison of underlying results over time.

About IMS Health

IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. Our 7,000 services experts connect configurable SaaS applications to 15+ petabytes of complex healthcare data in the IMS One™ cloud platform, delivering unique insights into diseases, treatments, costs and outcomes. The company’s 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.

As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at www.imshealth.com.